Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Forty Seven enters trial collaborations with Merck KGAA and Genentech

Executive Summary

Forty Seven Inc. entered into trial collaborations with Merck KGAA and Genentech Inc. to evaluate its own antibody Hu5F9G4 as a potential combination therapy for ovarian and bladder cancers and leukemia.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Trial Collaborations

Related Companies

Advertisement
UsernamePublicRestriction

Register